Medscape

Assay for HIV Drug Resistance Provides Quick, Low-Cost Results for Reverse Transcriptase Inhibitors

The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...
The Scientist

Postdoc Portrait: Archana Joon Explores Host-Pathogen Dynamics in the HSV/HIV Syndemic

Postdoctoral researcher Archana Joon at Albert Einstein College of Medicine studies how herpes simplex virus reshapes the ...
Fierce Pharma

Gilead christens Bixlenvo with FDA nod for new HIV treatment combo tablet

The FDA approval of Bixlenvo tees up a new HIV treatment option for virologically suppressed adults, including those on ...
Forbes

A New Strategy May Finally Put An HIV Vaccine Within Reach

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. A new sequential immunization strategy shows strong promise for an HIV vaccine, a ...
CNBC

Gilead says its twice-yearly shot cut HIV infections by 96% in trial

Gilead's twice-yearly shot reduced HIV infections by 96% in a second large study, the company said. The data sets the stage for likely FDA approval of lenacapavir for HIV prevention. Shares rose 3 ...

Gilead’s HIV Business is Surging, but is the Company Too Dependent on One Franchise?

Gilead Sciences, Inc. (NASDAQ:GILD) delivered strong fiscal Q2 2026 results, with total revenue rising 10% year over year to ...
Forbes

Breakthrough HIV Drug Is Out Of Reach For Many Who Need It Most

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. NAKURU, KENYA - 2026/03/26: A healthcare worker fills a syringe with a dose of lenacapavir, ...
Science Daily

New drug shows promise in clearing HIV from brain

An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new study. By targeting infected cells in the brain, drug may clear ...
Rutland Herald

U.S. FDA approves ViiV Healthcare’s Tivicay PD, helping close a critical HIV treatment gap for young children

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Shionogi as a shareholder, today announced that the U.S. Food and Drug Administration (FDA) has approved Tivicay PD ...

South Dakota sees rise in HIV spread among people who inject drugs

As of July 2026, there have been 34 newly diagnosed cases of HIV this year and 50% are reported among individuals who inject drugs.